Sands, Jacob
Dana-Farber Cancer Institute
3 papers on CoChatORCID 0000-0003-4663-7464
Most cited papers
- Verified
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 130
- Verified
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
Ahn, M.-J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., et al. (2025) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 66
- Verified
Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy
Yambayev, I., Sullivan, T. B., Rieger-Christ, K. M., Servais, E. L., Stock, C. T., Quadri, S. M., Sands, J. M., Suzuki, K., & Burks, E. J. (2022) · Lung Cancer
Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free